Novartis’ Tschudin on transforming sales via the pharma’s latest reorg 

Getting better sales out of the products that make it to market is a central component of Novartis’ recent shake-up, according to Marie-France Tschudin, the recently appointed chief commercial officer and head of the Innovative Medicines International unit. By improving access for patients with new approaches, she hopes to deliver more for them, and fill a hole in revenues that is hurting the company.

Tschudin has led the pharmaceutical business unit at  Novartis AG (SIX:NOVN; NYSE:NVS) since 2019. Her role expanded on April 4 when CEO Vas Narasimhan announced a major reorganization that merged Novartis Oncology with Novartis Pharmaceuticals, giving Tschudin responsibility for the international commercial business, and appointing Victor Bulto as her counterpart in the U.S. At the same time, Tschudin was made CCO, with oversight of global strategy for Novartis’ pipeline and marketed products, bridging scientific and commercial activities. ...